Clinical trial · Interventional
Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients
The Role of Intravenous Iron to Prevent Anemia in Women With Breast Cancer Receiving (Neo)Adjuvant Chemotherapy
NCT01168505CI-TRIAL-00014605unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study to evaluate the efficacy of intravenous iron supplementation in the prevention of anemia in patients receiving (neo)adjuvant breast cancer regimens.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ferric hydroxide saccharate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- no iron supplentation
- type
- EXPERIMENTAL
- label
- iron supplement
- interventionNames
- Drug: ferric hydroxide saccharate
Primary outcomes (1)
- measure
- Evaluate the efficacy of intravenous iron supplementation in the prevention of anemia in patients receiving (neo)adjuvant breast cancer regimens
- timeFrame
- 18 weeks
- description
- Anemia prevention defined by hemoglobin levels
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Women older than 18 years 2. Patient with operated breast cancer with indication for (NEO)adjuvant therapy 3. They must have hemoglobin levels within the normal range (\> 12g/dL), absence of renal and hepatic dysfunction as assessed by serum levels of urea, creatinine, AST, ALT. 4. Lack of folic acid deficiency and vitamin B12 5. Able to provide written informed consent. Exclusion Criteria: 1. Use of any oral supplement containing iron; 2. Patients who have iron overload as defined by serum ferritin\> 800 microg / L or transferrin saturation\> 40%; 3. Patients who are pregnant or breastfeeding; 4. History of active infection or active bleeding except menstruation; 5. History of HIV or hepatitis B or C - clinically important; -
References
Publications (0)
Data not yet available
No reference posted for this study.